某院原发性肺癌化疗方案中抗肿瘤药及抗肿瘤治疗辅助药医嘱评价

Review analysis of medical orders on antineoplastic and anti-tumor adjuvant medication in the treatment of primary lung cancer chemotherapy

目的分析该院原发性肺癌化疗方案中抗肿瘤药物及抗肿瘤治疗辅助药用药情况,以促进临床合理用药。方法回顾性分析该院2015年11月—2016年10月120份原发性肺癌化疗病案中抗肿瘤药物和抗肿瘤辅助用药使用情况和这些病历在静脉输液配置中心医嘱审核情况。结果在120份原发性肺癌化疗病历中,抗肿瘤治疗药10条(6份病案)医嘱不合理;抗肿瘤治疗辅助药物不合理使用的情况,共有24条(14份病案),两者共计16份病例出现不合理用药情况,占总病例数的13.33%。结论该院原发性肺癌化疗病历中的抗肿瘤治疗药使用基本合理,但抗肿瘤治疗辅助药存在一定的不合理使用情况。医院应建立监管机制,确保抗肿瘤药物的安全合理使用。

Objective Review analysis of medical advice on antineoplastic and antineoplastic adjuvant medication in the treatment of primary lung cancer chemotherapy and to promote rational drug use. Methods Medical order on antineoplastic and antineoplastic adjuvant medicationin were analyzed in 120 medical records with primary lung cancer from November 2015 to October 2016. Results A total of 16 medical records were not reasonable accounting for 13. 33% among these 120 medical records. 10 medical orders( 6 medical records) on antineoplastic and 24 medical orders( 14 medical records) on antineoplastic adjuvant medication were not reasonable.Conclusions The medical orders on antineoplastic in the treatment of primary lung cancer chemotherapy are basically reasonable.However,there are certain unreasonable use in antineoplastic adjuvant medication. This hospital should establish a supervision mechanism to improve our rational drug use level.